Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection

This Week: and lots more… As many of you will know, we have made something of a name for ourselves by tracking psychedelic patents for almost three years, thanks to our collaborators over at Calyx Law.But patents aren’t the only type of Intellectual Property. There are also trade secrets (such as the ‘Psilocybin Trade Secrets’ that are the subject of Terran Biosciences’ lawsuit against COMPASS…

Source